Add like
Add dislike
Add to saved papers

Hemodialysis shortens long in vitro closure times as measured by the PFA-100.

BACKGROUND: Hemorrhagic complications are commonly encountered in patients with end-stage renal disease (ESRD). Uremic patients show a bleeding diathesis mainly due to abnormalities in platelet function. There are several tests to detect and measure impairment of hemostasis in these patients, but none appear to be ideal. In recent years, the PFA-100 (platelet function analyzer) was introduced to measure primary, platelet-dependent hemostasis. In this study, the effect of hemodialysis on platelet function was evaluated using the PFA-100 in patients with ESRD.

MATERIAL/METHODS: The study was performed on 45 patients with ESRD undergoing regular hemodialysis aged between 20-76 years (median: 54 years). Collagen/epinephrine (CEPI) and collagen/ADP (CADP) closure times were measured before and after the hemodialysis session using the PFA.

RESULTS: CEPI (normal range: 85-165 sec) was significantly shortened from 230+/-60 to 206+/-63 sec after hemodialysis (p<0.05). The CADP (normal range: 71-118 sec) was also shortened by hemodialysis from 177+/-69 to 169+/-71 sec (p>0.05). CEPI closure times of 10 (26%) in 38 patients with long CT returned to normal after hemodialysis. CADP closure times of 9 (25%) of 36 patients with long CT returned to normal after hemodialysis.

CONCLUSIONS: This study confirms the existence of a dysfunction of primary hemostasis in patients with ESRD, and hemodialysis has the ability to correct some part of the hemostatic disturbances. As a sensitive, specific, reproducible, easy to perform, and noninvasive test for platelet-related primary hemostasis, the PFA-100 system may become a useful tool for an overall evaluation of primary hemostasis in patients with ESRD.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app